Luke Miels

2 articles

GSK shares dive as weaker vaccine sales unnerve investors

GSK shares tumbled after third-quarter results showed vaccine sales dipping despite overall revenue growth, sparking investor concern over patent expiries. CEO Luke Miels outlined cost-saving measures

theguardian · 2026-10-28 23:34

GSK to buy cancer drug developer Nuvalent for $10.6 billion

GSK announced plans to acquire Nuvalent for $10.6 billion, aiming to expand its small-molecule kinase inhibitor portfolio for treatment-resistant cancers under new CEO Luke Miels.

cen · 2026-06-09 00:00